Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Ann OncolJun 17, 2026 (epub)
Clinical ResearchOncology (Medical)
F Han, Y Q Xiang, X H Wang et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized trial evaluated becotatug vedotin in patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) after failure of ≥2 systemic therapies. The study found that becotatug vedotin resulted in a higher objective response rate (ORR) of 30.2% compared to 11.5% for chemotherapy (P = 0.003) and significantly improved progression-free survival (PFS) with a median of 5.82 months versus 2.83 months.
Key findings
- Becotatug vedotin achieved an ORR of 30.2% compared to 11.5% for chemotherapy (P = 0.003).
- Median PFS was significantly longer with becotatug vedotin at 5.82 months versus 2.83 months (HR 0.63, P = 0.01).
- Interim OS analysis showed a median OS of 17.08 months for becotatug vedotin versus 11.99 months for chemotherapy (HR 0.73, P = 0.15).
Why it matters
The findings suggest that becotatug vedotin may offer a more effective treatment option for patients with recurrent/metastatic NPC who have limited alternatives after prior therapies, potentially improving patient outcomes.